Covalon Technologies Ltd
XTSX:COV

Watchlist Manager
Covalon Technologies Ltd Logo
Covalon Technologies Ltd
XTSX:COV
Watchlist
Price: 1.92 CAD -2.54% Market Closed
Market Cap: 53m CAD

Covalon Technologies Ltd
Investor Relations

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of patent-protected medical products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-09-03. The firm uses science and technology to help solve medical challenges associated with prevention, detection and management of areas such as infection, tissue repair and medical devices. Its products include Advanced Wound Care, Vascular Access, Perioperative Care and Urology. Advanced Wound Care is designed for the treatment of a range of wounds and offers CovaWound and ColActive brands. Vascular Access portfolio includes CovaView IV, a transparent film dressing that provides an effective barrier against external contaminants, including fluid, bacteria, and yeast. Perioperative care refers to the three Phases of surgery, including preoperative, intraoperative, and postoperative care and its brands include MediClear and SurgiClear.

Show more
Loading
COV
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Aug 21, 2025
AI Summary
Q3 2025

Sequential Revenue Growth: Covalon reported Q3 revenue of $8.4 million, up more than 10% from Q2, led by strong sales in the U.S. advanced wound care channel.

Year-Over-Year Decline: Despite the sequential growth, Q3 revenue was 9% below last year's Q3, which was Covalon's highest revenue quarter in 2024.

Margins Impacted by One-Time Charges: Gross profit and margin were down, mainly due to over $800,000 in charges for obsolete or slow-moving inventory. Excluding these, adjusted gross margin improved to over 55%.

International Expansion: The company saw international revenue growth of more than 35% year-to-date and made progress registering products and signing new distribution deals in several countries.

Cash Position: Covalon ended the quarter with over $18 million in cash, up almost $9 million year-over-year and has increased its cash on hand for five consecutive quarters.

Positive Outlook: Management expects sequential revenue growth to continue in Q4 and is bullish about strong growth into next year.

New Indications & Use Cases: Innovation is driving new use cases for existing products, such as the "Mudflap" application for CovaClear IV, which delivers both clinical and economic benefits.

Customer Retention: Covalon retained 100% of its top 50 U.S. hospital customers and achieved 25% year-to-date revenue growth from them.

Key Financials
Revenue
$8.4 million
Adjusted Gross Margin
over 55%
Adjusted EBITDA
just under $1 million
Year-to-Date Revenue Growth
8%
Trailing 12 Month Revenue Growth
13%
International Revenue Growth YTD
over 35%
Cash Position
just over $18 million
3-Year Compounded Annual Growth Rate
27%
Top 50 U.S. Hospital Customer Retention
100%
Top 50 U.S. Hospital Revenue Growth YTD
25%
New Hospital Accounts Added YTD
65
Earnings Call Recording
Other Earnings Calls

Management

Mr. Amir Boloor CFA
Executive Chairman
No Bio Available
Mr. Ronald Hebert
Senior Vice President of Growth
No Bio Available
Mr. Brent Ashton
CEO & Director
No Bio Available
Dr. Valerio DiTizio
Co-Founder, Chief Scientific Officer & VP
No Bio Available
Ms. Katie Martinovich
Interim Chief Financial Officer
No Bio Available
Ms. Kim Crooks
Senior Vice President of Operations
No Bio Available
Mr. Greg Leszczynski
Vice President of Human Resources
No Bio Available
Gerry Arambula
President of Covalon Technologies AG Ltd.
No Bio Available
Mr. Hamed Abbasian
Vice President of Business Development
No Bio Available
Emily Hill
Executive Assistant to the CEO
No Bio Available

Contacts

Address
ONTARIO
Mississauga
1660 Tech Avenue, Unit 5
Contacts
+19055688400.0
www.covalon.com